ArticleCardiology journal2026
Safety of ultrasound-assisted catheter-directed thrombolysis for central pulmonary embolism in intermediate-high-risk patients with increased bleeding risk in a rural hospital setting.
Article in Cardiology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe EkoSonic Endovascular System (EKOS™) is an ultrasound-assisted catheter-directed thrombolysis (UACDT) device, which is becoming more popular for treatment of pulmonary embolism (PE) in patients with intermediate-high and high risk. Ultrasound waves help clot fragmentation and dissolution, therefore requiring less thrombolytic agent. With lower doses of thrombolysis, the bleeding risk is reduced but not eliminated. We aimed to evaluate the safety of this therapy in intermediate-high-risk central PE with intermediate and high bleeding risk.
methodsWe retrospectively analyzed the database of a rural hospital between March 2021 and July 2024 for UACDT with EKOS™ in patients with intermediate-high-risk central PE and Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) score ≥ 1. We evaluated procedure-related complications, bleeding events within the first 7 days, the need for further intervention, and all-cause in-hospital mortality.
resultsThirty patients underwent UACDT with EKOS™. Their mean age was 68 ± 15.6 years (30% ≥ 80 years). Deep vein thrombosis was present in 16 patients (53.3%). Access was via the brachial vein (23.3%) or the common femoral vein (76.7%). One patient had major bleeding from the access site. There were no other procedure-related major complications. Two patients had minor bleeding events. All bleeding events were managed conservatively without the need for blood transfusion. One patient (3.3%) died in-hospital due to multiple organ failure, and 86% of the patients (26/30) had no complications.
conclusionsOur analysis suggests that UACDT with EKOS™ is safe for the management of intermediate-high-risk central PE in patients with intermediate and high bleeding risk even in a rural hospital setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.